On December 10, 2025, the FDA convened an expert panel of urologists, endocrinologists, and men's health specialists to review the regulatory framework surrounding testosterone replacement therapy. The panel's recommendations were sweeping: remove testosterone from the Schedule III controlled substance list, eliminate outdated prostate cancer contraindications from product labels, and expand the approved indication to include any man with clinically low testosterone and associated symptoms — not just those with a diagnosed underlying medical condition.
Why It Matters
If testosterone is descheduled and indications broadened, the addressable market for telehealth TRT platforms like Hims, Ro, and T-TIME could expand dramatically. An estimated 20 million American men have low testosterone, but current regulatory barriers suppress prescribing. Removing the controlled substance designation would ease pharmacy stocking, reduce prescription monitoring burden, and likely accelerate the already-booming online TRT market."Testosterone is still regulated as if it were a dangerous, performance-enhancing drug from the 1980s," said Dr. Helen Bernie of Indiana University. Dr. John Mulhall of Memorial Sloan Kettering added that "thousands of patients in need of testosterone therapy have been and are being deprived of it." Dr. Landon Trost of the Male Fertility Clinic noted the Schedule III designation causes physician hesitancy and pharmacy supply limitations, driving men to unregulated "pop-up T clinics."
The panel's confidence was bolstered by the TRAVERSE trial, a large randomized, placebo-controlled study published in the New England Journal of Medicine, which found TRT was not associated with higher rates of heart attack or stroke versus placebo. The FDA had already removed a cardiovascular black-box warning from testosterone labels in February 2025.
The comment period on the FDA's request for information closed on February 9, 2026. While the panel's recommendations are advisory, they signal a potential paradigm shift. Descheduling would require action from the DEA and potentially Congress, since testosterone was placed in Schedule III through the Anabolic Steroids Control Act of 1990.
Sources
- FDA Panel on Testosterone Replacement Therapy — NBC News
- FDA Panel Calls for Easing Restrictions on Testosterone — Healthline
- FDA Panel Calls for Easing Restrictions — RAPS
- FDA Panel Supports Expanding Testosterone Therapy — Healio
Update — 2026-03-14
Initial entry — story first created.